Efficacy and safety of dupilumab in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis

被引：0
|
作者：
Paller, Amy S. [1 ,2 ]
Cork, Michael J. [3 ]
Siegfried, Elaine C. [4 ,5 ]
Simpson, Eric L. [6 ]
Wollenberg, Andreas [7 ]
Gonzalez, Mercedes E. [8 ]
Sun, Yiping [9 ]
O'Malley, John T. [10 ]
Bansal, Ashish [9 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Ann & Robert H Lurie Childrens Hosp, Chicago, IL USA
[3] Univ Sheffield, Sheffield Dermatol Res, Sheffield, S Yorkshire, England
[4] St Louis Univ, St Louis, MO 63103 USA
[5] Cardinal Glennon Childrens Hosp, St Louis, MO USA
[6] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[7] Ludwig Maximilians Univ Munchen, Munich, Germany
[8] Univ Miami, Miller Sch Med, Miami, FL 33136 USA
[9] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[10] Sanofi, Cambridge, MA USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 187卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
O04
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of dupilumab in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis
    Paller, A. S.
    Simpson, E. L.
    Siegfried, E. C.
    Cork, M. J.
    Wollenberg, A.
    Arkwright, P. D.
    Soong, W.
    Gonzalez, M. E.
    Schneider, L. C.
    Sidbury, R.
    Lockshin, B.
    Wang, Z.
    Mannent, L. P.
    Amin, N.
    Sun, Y.
    Laws, E.
    Akinlade, B.
    Kosloski, M. P.
    Dubost-Brama, A.
    O'Malley, J. T.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E173 - E173
  • [2] Efficacy and safety of dupilumab in children aged ≥6 months to <6 years with moderate-to-severe atopic dermatitis
    Paller, Amy S.
    Siegfried, Elaine C.
    Simpson, Eric L.
    Wollenberg, Andreas
    Gonzalez, Mercedes E.
    Sidbury, Robert
    Lockshin, Benjamin
    Xiao, Jing
    O'Malley, John T.
    Bansal, Ashish
    ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 561 - 561
  • [3] EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 6 MONTHS TO 5 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Worrell, Richard
    Paller, Amy S.
    Siegfried, Elaine C.
    Simpson, Eric L.
    Wollenberg, Andreas
    Gonzalez, Mercedes E.
    Sidbury, Robert
    Lockshin, Benjamin
    Dubost-Brama, Ariane
    Bansal, Ashish
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 31 - 32
  • [4] DUPILUMAB REDUCES ITCH IN CHILDREN WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AGED 6 MONTHS TO 5 YEARS
    Paller, A. S.
    Siegfried, E. C.
    Yosipovitch, G.
    Kwatra, S. G.
    Praestgaard, A.
    Prescilla, R.
    Wang, J.
    VALUE IN HEALTH, 2023, 26 (06) : S57 - S58
  • [5] Dupilumab Reduces Itch in Children with Moderate-to-Severe Atopic Dermatitis Aged 6 Months to 5 Years
    Paller, Amy S.
    Siegfried, Elaine C.
    Yosipovitch, Gil
    Kwatra, Shawn G.
    Praestgaard, Amy
    Wang, Zhixiao
    Prescilla, Randy
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB151 - AB151
  • [6] Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis
    Paller, A.
    Guttman-Yassky, E.
    Boguniewicz, M.
    Sun, Y.
    Wolfe, K.
    Dillon, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : S51 - S51
  • [7] Dupilumab Improves Family Quality of Life in Children Aged 6 months to 5 Years With Moderate-to-Severe Atopic Dermatitis
    Paller, Amy
    Simpson, Eric
    Siegfried, Elaine
    Preastgaard, Amy
    Wang, Zhixiao
    Prescilla, Randy
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB150 - AB150
  • [8] Dupilumab Reduces Biomarkers Indicative of Type 2 Inflammation in Children Aged ≥ 6 Months to < 6 YearsWith Moderate-to-Severe Atopic Dermatitis
    Pinter, Andreas
    Paller, Amy
    Guttman-Yassky, Emma
    Boguniewicz, Mark
    Sun, Yiping
    Wolfe, Kelley
    Dillon, Myles
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 100 - 100
  • [9] Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis
    Paller, A. S.
    Guttman-Yassky, E.
    Boguniewicz, M.
    Sun, Y.
    Wolfe, K.
    Kroeller-Schoen, S.
    ALLERGOLOGIE, 2022, 45 (08) : 621 - 622
  • [10] 411 Long term laboratory safety of dupilumab in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis
    Siegfried, Elaine
    Cork, Michael J.
    Lockshin, Benjamin
    Boguniewicz, Mark
    Uppal, Sumeet
    Khokhar, Faisal A.
    Bansal, Ashish
    Sierka, Debra
    Cyr, Sonya
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
12345